» Articles » PMID: 33656715

Emerging Technologies for the Treatment of COVID-19

Overview
Date 2021 Mar 3
PMID 33656715
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The new coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), turned into a pandemic affecting more than 200 countries. Due to the high rate of transmission and mortality, finding specific and effective treatment options for this infection is currently of urgent importance. Emerging technologies have created a promising platform for developing novel treatment options for various viral diseases such as the SARS-CoV-2 virus. Here, we have described potential novel therapeutic options based on the structure and pathophysiological mechanism of the SARS-CoV-2 virus, as well as the results of previous studies on similar viruses such as SARS and MERS. Many of these approaches can be used for controlling viral infection by reducing the viral damage or by increasing the potency of the host response. Owing to their high sensitivity, specificity, and reproducibility, siRNAs, aptamers, nanobodies, neutralizing antibodies, and different types of peptides can be used for interference with viral replication or for blocking internalization. Receptor agonists and interferon-inducing agents are also potential options to balance and enhance the innate immune response against SARS-CoV-2. Solid evidence on the efficacy and safety of such novel technologies is yet to be established although many well-designed clinical trials are underway to address these issues.

Citing Articles

A Multiple-Center, Retrospective Study of Characteristics and Outcomes of Hospitalized COVID-19 Patients with Cardiovascular Disease in North Iran.

Pournajaf A, Halaji M, Sadeghi F, Chehrazi M, Javanian M, Bayani M Ethiop J Health Sci. 2023; 33(1):3-12.

PMID: 36890939 PMC: 9987289. DOI: 10.4314/ejhs.v33i1.2.


A case-based systematic review on the SARS-COVID-2-associated cerebrovascular diseases and the possible virus routes of entry.

Lashkari A, Ranjbar R J Neurovirol. 2021; 27(5):691-701.

PMID: 34546547 PMC: 8454012. DOI: 10.1007/s13365-021-01013-8.

References
1.
Agostini M, Andres E, Sims A, Graham R, Sheahan T, Lu X . Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9(2). PMC: 5844999. DOI: 10.1128/mBio.00221-18. View

2.
Brown A, Won J, Graham R, Dinnon 3rd K, Sims A, Feng J . Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019; 169:104541. PMC: 6699884. DOI: 10.1016/j.antiviral.2019.104541. View

3.
de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T . Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020; 117(12):6771-6776. PMC: 7104368. DOI: 10.1073/pnas.1922083117. View

4.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

5.
Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252-6. PMC: 1746980. DOI: 10.1136/thorax.2003.012658. View